Lonza has completed the carve-out of its Lonza Specialty Ingredients, as announced in February. The business, temporarily known as LSI, will be relaunched shortly under a different name. It is now owned by Herens HoldCo, an entity controlled by private equity firms Bain Capital and Cinven, who acquired it for an enterprise value of CHF 4.2 billion.

Lonza its to expand its two-year collaboration with Moderna to manufacture the drug substance for Moderna’ COVID-19 vaccine. This will lead to further expansion at its main site in Visp, Switzerland, as will another small molecule complex, which includes a dedicated line for antibody-drug conjugates (ADCs) for an unnamed customer.

Following a long period of speculation, Lonza has entered into a definitive agreement to sell its Lonza Specialty Ingredients (LSI) business to private equity firms Bain Capital and Cinven for CHF 4.2 billion in order to focus entirely on healthcare. The deal is expected to close in 2H, subject to customary closing conditions.

Lonza has recently announced three specific investments in the pharma sector in recent weeks. It will build two new customer-dedicated conjugation suites for antibody-drug conjugates (ADCs) at Visp, Switzerland, while adding particle engineering and drug product development at two sites in the US.

Both Croda International and Novasep are involved in some of the vaccines nearing approval for use in the treatment of COVID-19 it has emerged. This follows on from many other announcements of development agreements involving other fine chemical companies earlier in the year.

Lonza has opened the first of two manufacturing suites at its main site in Visp, Switzerland, for the manufacture of antibody-drug conjugate (ADC) linkers or payloads. This came shortly after an unrelated deal to manufacture antibodies to treat COVID-19 for AstraZeneca and the arrival of a new CEO with a Big Pharma background.

The ongoing race to develop the first effective vaccines for the treatment of COVID-19 continues to generate manufacturing and development agreements between pharmaceutical giants, biotechs and CDMOs.

Most recently, Sterling Pharma Solutions agreed to carry out final purification of drug product for Moleculin Biotech’s WP1122 drug candidate from its site in Cary, North Carolina. Moleculin is about to submit an IND for this to the FDA and wanted a reliable source of supply in the US.